**Supplementary Table 3**

Situations with potential to increase false-positive or false-negative rates of thrombophilia tests

|  |  |
| --- | --- |
| Situation | Tests Potentially Affected |
| Receiving anticoagulant therapy at time of test |  |
| Unfractionated heparin, low molecular weight heparin, rivaroxaban | Antithrombin Antigen  Antithrombin, Enzymatic Activity  Activated Protein C (APC) Resistance  Lupus Anticoagulant  Protein C, Functional  Protein C, Total  Protein S, Free  Protein S, Functional  Protein S, Total |
| Warfarin | Activated Protein C (APC) Resistance  Lupus Anticoagulant  Protein C, Functional  Protein C, Total  Protein S, Free  Protein S, Functional  Protein S, Total |
| Acute thrombosis at time of test | Antithrombin Antigen  Antithrombin, Enzymatic Activity  β2-glycoprotein 1, IgG Antibodies  β2-glycoprotein 1, IgM Antibodies  Cardiolipin IgG Antibodies  Cardiolipin IgM Antibodies  Lupus Anticoagulant  Protein C, Functional  Protein C, Total  Protein S, Free  Protein S, Functional  Protein S, Total |
| Pregnant or < 8 weeks post-partum at time of test | Antithrombin Antigen  Antithrombin, Enzymatic Activity  Protein C, Functional  Protein C, Total  Protein S, Free  Protein S, Functional  Protein S, Total |
| Receiving estrogen-containing medications at time of test | Protein S, Functional  Protein S, Total |